Involvement of prostaglandin receptors (EPR2-4) in in vivo immunosuppression of PGE2 in rat skin transplant model

Yoshimi Fujimoto, Hiromi Iwagaki, Michitaka Ozaki, Tetsuya Ogino, Hiroshi Murata, Sheng Sun Dong, Hiroshi Sadamori, Kohka Takahashi Hideo, Noriaki Tanaka, Takahito Yagi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Prostaglandin E2 (PGE2) is known to modulate immune responses and is widely viewed as a general immunosuppressant. There have been recognized four receptors for PGE2 (EP1-EP4 receptor) so far, and EP2 and EP4 receptors are mainly involved in the immunosuppressive effect of PGE2 in vitro. In the present study we examined the in vivo immunosuppressive effects of selective EP receptor agonists using a high-responder rat skin transplantation model. Materials and methods: Skin allografts from ACI donors were transplanted onto LEW recipients. Agents were injected everyday between day 0 and day 5 after skin transplantation at the dose of 300 μg/kg subcutaneously. Survival of the skin allograft, histological changes and changes of the intragraft cytokine expressions were analyzed using the reverse transcription polymerase chain reaction (RT-PCR). We also assessed the mixed lymphocyte reaction (MLR) assay using splenocytes. Results: PGE2 significantly prolonged allograft survival (18.8 ± 1.5 days) compared with untreated control (14.8 ± 0.8 days). EP2R + EP3R + EP4R agonists also prolonged allograft survival (18.0 ± 1.0 days) although EP3R agonist or EP2R + EP4R agonists alone failed (15.5 ± 0.7, 15.4 ± 1.3 days, respectively). RT-PCR analysis in the skin grafts demonstrated IL-10 up-regulation and IFN-γ down-regulation in all groups except untreated control and EP2R agonist-treated groups. MLR was significantly reduced in groups of EP2R + EP4R agonists, EP2R + EP3R + EP4R agonists and PGE2, compared with untreated control. Conclusions: The effect of PGE2 to prolong the survival of skin transplant requires the action of a combination of three receptors, i.e., EP2 + EP3 + EP4.

Original languageEnglish
Pages (from-to)1131-1139
Number of pages9
JournalInternational Immunopharmacology
Volume5
Issue number7-8
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Prostaglandin Receptors
Dinoprostone
Immunosuppression
Transplants
Skin
Allografts
Immunosuppressive Agents
Mixed Lymphocyte Culture Test
Skin Transplantation
Reverse Transcription
Polymerase Chain Reaction
Interleukin-10
Up-Regulation
Down-Regulation
Cytokines

Keywords

  • EP receptor agonists
  • Immunosuppression
  • Prostaglandin E2
  • Skin transplantation

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Involvement of prostaglandin receptors (EPR2-4) in in vivo immunosuppression of PGE2 in rat skin transplant model. / Fujimoto, Yoshimi; Iwagaki, Hiromi; Ozaki, Michitaka; Ogino, Tetsuya; Murata, Hiroshi; Dong, Sheng Sun; Sadamori, Hiroshi; Hideo, Kohka Takahashi; Tanaka, Noriaki; Yagi, Takahito.

In: International Immunopharmacology, Vol. 5, No. 7-8, 07.2005, p. 1131-1139.

Research output: Contribution to journalArticle

Fujimoto, Y, Iwagaki, H, Ozaki, M, Ogino, T, Murata, H, Dong, SS, Sadamori, H, Hideo, KT, Tanaka, N & Yagi, T 2005, 'Involvement of prostaglandin receptors (EPR2-4) in in vivo immunosuppression of PGE2 in rat skin transplant model', International Immunopharmacology, vol. 5, no. 7-8, pp. 1131-1139. https://doi.org/10.1016/j.intimp.2005.01.014
Fujimoto, Yoshimi ; Iwagaki, Hiromi ; Ozaki, Michitaka ; Ogino, Tetsuya ; Murata, Hiroshi ; Dong, Sheng Sun ; Sadamori, Hiroshi ; Hideo, Kohka Takahashi ; Tanaka, Noriaki ; Yagi, Takahito. / Involvement of prostaglandin receptors (EPR2-4) in in vivo immunosuppression of PGE2 in rat skin transplant model. In: International Immunopharmacology. 2005 ; Vol. 5, No. 7-8. pp. 1131-1139.
@article{191103111aac4c908172786771926cdf,
title = "Involvement of prostaglandin receptors (EPR2-4) in in vivo immunosuppression of PGE2 in rat skin transplant model",
abstract = "Background: Prostaglandin E2 (PGE2) is known to modulate immune responses and is widely viewed as a general immunosuppressant. There have been recognized four receptors for PGE2 (EP1-EP4 receptor) so far, and EP2 and EP4 receptors are mainly involved in the immunosuppressive effect of PGE2 in vitro. In the present study we examined the in vivo immunosuppressive effects of selective EP receptor agonists using a high-responder rat skin transplantation model. Materials and methods: Skin allografts from ACI donors were transplanted onto LEW recipients. Agents were injected everyday between day 0 and day 5 after skin transplantation at the dose of 300 μg/kg subcutaneously. Survival of the skin allograft, histological changes and changes of the intragraft cytokine expressions were analyzed using the reverse transcription polymerase chain reaction (RT-PCR). We also assessed the mixed lymphocyte reaction (MLR) assay using splenocytes. Results: PGE2 significantly prolonged allograft survival (18.8 ± 1.5 days) compared with untreated control (14.8 ± 0.8 days). EP2R + EP3R + EP4R agonists also prolonged allograft survival (18.0 ± 1.0 days) although EP3R agonist or EP2R + EP4R agonists alone failed (15.5 ± 0.7, 15.4 ± 1.3 days, respectively). RT-PCR analysis in the skin grafts demonstrated IL-10 up-regulation and IFN-γ down-regulation in all groups except untreated control and EP2R agonist-treated groups. MLR was significantly reduced in groups of EP2R + EP4R agonists, EP2R + EP3R + EP4R agonists and PGE2, compared with untreated control. Conclusions: The effect of PGE2 to prolong the survival of skin transplant requires the action of a combination of three receptors, i.e., EP2 + EP3 + EP4.",
keywords = "EP receptor agonists, Immunosuppression, Prostaglandin E2, Skin transplantation",
author = "Yoshimi Fujimoto and Hiromi Iwagaki and Michitaka Ozaki and Tetsuya Ogino and Hiroshi Murata and Dong, {Sheng Sun} and Hiroshi Sadamori and Hideo, {Kohka Takahashi} and Noriaki Tanaka and Takahito Yagi",
year = "2005",
month = "7",
doi = "10.1016/j.intimp.2005.01.014",
language = "English",
volume = "5",
pages = "1131--1139",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "7-8",

}

TY - JOUR

T1 - Involvement of prostaglandin receptors (EPR2-4) in in vivo immunosuppression of PGE2 in rat skin transplant model

AU - Fujimoto, Yoshimi

AU - Iwagaki, Hiromi

AU - Ozaki, Michitaka

AU - Ogino, Tetsuya

AU - Murata, Hiroshi

AU - Dong, Sheng Sun

AU - Sadamori, Hiroshi

AU - Hideo, Kohka Takahashi

AU - Tanaka, Noriaki

AU - Yagi, Takahito

PY - 2005/7

Y1 - 2005/7

N2 - Background: Prostaglandin E2 (PGE2) is known to modulate immune responses and is widely viewed as a general immunosuppressant. There have been recognized four receptors for PGE2 (EP1-EP4 receptor) so far, and EP2 and EP4 receptors are mainly involved in the immunosuppressive effect of PGE2 in vitro. In the present study we examined the in vivo immunosuppressive effects of selective EP receptor agonists using a high-responder rat skin transplantation model. Materials and methods: Skin allografts from ACI donors were transplanted onto LEW recipients. Agents were injected everyday between day 0 and day 5 after skin transplantation at the dose of 300 μg/kg subcutaneously. Survival of the skin allograft, histological changes and changes of the intragraft cytokine expressions were analyzed using the reverse transcription polymerase chain reaction (RT-PCR). We also assessed the mixed lymphocyte reaction (MLR) assay using splenocytes. Results: PGE2 significantly prolonged allograft survival (18.8 ± 1.5 days) compared with untreated control (14.8 ± 0.8 days). EP2R + EP3R + EP4R agonists also prolonged allograft survival (18.0 ± 1.0 days) although EP3R agonist or EP2R + EP4R agonists alone failed (15.5 ± 0.7, 15.4 ± 1.3 days, respectively). RT-PCR analysis in the skin grafts demonstrated IL-10 up-regulation and IFN-γ down-regulation in all groups except untreated control and EP2R agonist-treated groups. MLR was significantly reduced in groups of EP2R + EP4R agonists, EP2R + EP3R + EP4R agonists and PGE2, compared with untreated control. Conclusions: The effect of PGE2 to prolong the survival of skin transplant requires the action of a combination of three receptors, i.e., EP2 + EP3 + EP4.

AB - Background: Prostaglandin E2 (PGE2) is known to modulate immune responses and is widely viewed as a general immunosuppressant. There have been recognized four receptors for PGE2 (EP1-EP4 receptor) so far, and EP2 and EP4 receptors are mainly involved in the immunosuppressive effect of PGE2 in vitro. In the present study we examined the in vivo immunosuppressive effects of selective EP receptor agonists using a high-responder rat skin transplantation model. Materials and methods: Skin allografts from ACI donors were transplanted onto LEW recipients. Agents were injected everyday between day 0 and day 5 after skin transplantation at the dose of 300 μg/kg subcutaneously. Survival of the skin allograft, histological changes and changes of the intragraft cytokine expressions were analyzed using the reverse transcription polymerase chain reaction (RT-PCR). We also assessed the mixed lymphocyte reaction (MLR) assay using splenocytes. Results: PGE2 significantly prolonged allograft survival (18.8 ± 1.5 days) compared with untreated control (14.8 ± 0.8 days). EP2R + EP3R + EP4R agonists also prolonged allograft survival (18.0 ± 1.0 days) although EP3R agonist or EP2R + EP4R agonists alone failed (15.5 ± 0.7, 15.4 ± 1.3 days, respectively). RT-PCR analysis in the skin grafts demonstrated IL-10 up-regulation and IFN-γ down-regulation in all groups except untreated control and EP2R agonist-treated groups. MLR was significantly reduced in groups of EP2R + EP4R agonists, EP2R + EP3R + EP4R agonists and PGE2, compared with untreated control. Conclusions: The effect of PGE2 to prolong the survival of skin transplant requires the action of a combination of three receptors, i.e., EP2 + EP3 + EP4.

KW - EP receptor agonists

KW - Immunosuppression

KW - Prostaglandin E2

KW - Skin transplantation

UR - http://www.scopus.com/inward/record.url?scp=21144456524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144456524&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2005.01.014

DO - 10.1016/j.intimp.2005.01.014

M3 - Article

C2 - 15914318

AN - SCOPUS:21144456524

VL - 5

SP - 1131

EP - 1139

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 7-8

ER -